全球肌萎缩侧索硬化症市场：区域分析与预测（2025-2035）

随着人们对 ALS（肌萎缩侧索硬化症）认识的不断提高、基因研究的进步以及针对 ALS 的药物开发平臺的不断扩大，市场正在不断增长。

ALS 是一种影响运动神经元的进行进行性神经退化性疾病，随着科学的进步，治疗方法也变得越来越有针对性和有效性。

肌萎缩侧索硬化症（ALS）是一种以脑和脊髓运动神经元进行性退化为特征的疾病，会导致肌肉无力、肢体残疾，最终导致死亡。随着对此疾病分子机制的研究不断深入，创新治疗方案层出不穷。因此，ALS治疗市场正处于治疗方案选择的重要转捩点。

市场生命週期阶段

ALS 治疗市场目前正在经历快速演变，从以症状为中心的治疗转向以改变疾病进展为标靶治疗。目前，大多数治疗旨在减缓 ALS 的进展并缓解症状，但专注于该疾病遗传和分子机制的新干预方法正在兴起。具体而言，疾病修正治疗(DMT)、基因治疗和生物製药等方法有可能显着改变 ALS 的治疗方式。

北美凭藉其完善的医疗基础设施、较高的诊断率以及对ALS研究的大量投入，预计将继续占据全球ALS市场的主要份额。随着大型製药企业、研究机构和医疗保健提供者专注于该地区ALS治疗的进步，预计市场将进一步扩大。

本报告调查了全球肌萎缩侧索硬化症市场，并总结了主要趋势、影响市场的因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章全球肌萎缩侧索硬化症市场：产业展望

• 市场概况与生态系统
• 肌萎缩侧索硬化症的流行病学分析
  • 美国
  • 欧盟5国
• 市场趋势
• 临床试验
  • 按阶段
• 监理格局分析
  • 美国法律要求与框架
  • 欧盟法律要求和框架
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场限制
  • 市场机会

2. 全球肌萎缩侧索硬化症市场（按地区）

• 北美洲
  • 主要发现
  • 市场动态
  • 市场规模及预测
• 欧洲
  • 主要发现
  • 市场动态
  • 市场规模及预测
• 亚太地区
  • 主要发现
  • 市场动态
  • 市场规模及预测

3. 全球肌萎缩侧索硬化症市场：竞争基准化分析与公司简介

• 竞争格局
  • 各公司主要策略及发展
  • 重大进展分析
• 公司简介
  • Mitsubishi Tanabe Pharma Corporation
  • Biogen Inc.
  • Aquestive Therapeutics, Inc.
  • Ionis Pharmaceuticals
  • MediciNova
  • AB Science
  • Brainstorm-Cell Therapeutics
  • Italfarmaco SpA

第四章调查方法

Global Amyotrophic Lateral Sclerosis Market: Overview

The increasing awareness of ALS, advancements in genetic research, and a growing pipeline of therapeutic drugs targeting ALS are driving the market's growth. ALS is a progressive neurodegenerative disease affecting motor neurons, and with the advancements in science, the treatment landscape is becoming increasingly targeted and effective.

Amyotrophic lateral sclerosis is characterized by the progressive degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, disability, and eventually, death. With significant research efforts aimed at understanding its molecular mechanisms, innovative therapeutic solutions are emerging. As a result, the amyotrophic lateral sclerosis market is on the cusp of a breakthrough in terms of treatment options.

Market Lifecycle Stage

The market for amyotrophic lateral sclerosis treatments is in a rapidly evolving phase, shifting from symptomatic management toward more targeted therapies aimed at modifying the disease progression. While current treatments mainly focus on slowing the progression of amyotrophic lateral sclerosis and providing symptomatic relief, newer interventions are beginning to explore the genetic and molecular mechanisms underlying the disease. Disease-modifying therapies (DMTs), gene therapies, and biologic agents hold the potential to significantly alter the treatment landscape for amyotrophic lateral sclerosis patients.

North America is expected to maintain its dominant position in the global amyotrophic lateral sclerosis market, driven by a well-established healthcare infrastructure, a high rate of diagnosis, and substantial investment in amyotrophic lateral sclerosis research. Major pharmaceutical companies, research institutions, and healthcare providers are focused on advancing treatment options for amyotrophic lateral sclerosis in the region, which is expected to drive further market expansion.

Demand - Drivers and Limitations

The global amyotrophic lateral sclerosis market is driven by several key factors:

• Rising prevalence of amyotrophic lateral sclerosis cases will drive market demand
• Advances in genetic research, coupled with improved understanding of the molecular mechanisms involved in amyotrophic lateral sclerosis
• An increase in clinical trials and investments will accelerate the development of innovative treatments for amyotrophic lateral sclerosis

Limitations:

• The high cost of amyotrophic lateral sclerosis treatments may limit accessibility and market growth
• Lack of awareness in emerging markets will hinder the adoption of amyotrophic lateral sclerosis treatments

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: This report provides valuable insights for pharmaceutical companies and biotech firms looking to develop new amyotrophic lateral sclerosis treatments, focusing on genetic therapies, precision medicine, and biologics that target amyotrophic lateral sclerosis-specific molecular pathways. It helps identify emerging trends and the potential for breakthrough therapies that can modify disease progression.

Competitive Strategy: Pharmaceutical companies and healthcare providers can use the information in this report to evaluate the current competitive landscape, assess market trends, and develop strategies that ensure long-term success in the global amyotrophic lateral sclerosis Market. Understanding the major players, new entrants, and their strategies will help companies stay ahead of the competition.

Key Market Players and Competition Synopsis

The companies profiled in this report are selected based on expert insights, evaluating company coverage, product portfolio, and market penetration. Leading players in the global amyotrophic lateral sclerosis market include pharmaceutical companies who hold substantial shares of the market.

Some of the prominent names established in this market are:

• Mitsubishi Tanabe Pharma Corporation
• Biogen Inc.
• Aquestive Therapeutics, Inc.
• Ionis Pharmaceuticals
• MediciNova
• AB Science
• Brainstorm-Cell Therapeutics
• Italfarmaco S.p.A.

Table of Contents

Executive Summary

Scope of Study

Definition

Inclusion and Exclusion Criteria

1. Global Amyotrophic Lateral Sclerosis Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis of Amyotrophic Lateral Sclerosis
  • 1.2.1 U.S.
  • 1.2.2 EU5
• 1.3 Market Trends
• 1.4 Clinical Trials
  • 1.4.1 By Phase
• 1.5 Regulatory Landscape Analysis
  • 1.5.1 Legal Requirement and Framework in U.S.
  • 1.5.2 Legal Requirement and Framework in E.U.
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Amyotrophic Lateral Sclerosis Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 France
      • 2.2.3.1.3 Italy
      • 2.2.3.1.4 U.K.
• 2.3 Asia-Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.3.3.1.1 Japan

3. Global Amyotrophic Lateral Sclerosis Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Mitsubishi Tanabe Pharma Corporation
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Key Personnels
    • 3.2.1.5 Analyst View
  • 3.2.2 Biogen Inc.
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers / End Users
    • 3.2.2.4 Key Personnels
    • 3.2.2.5 Analyst View
  • 3.2.3 Aquestive Therapeutics, Inc.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers / End Users
    • 3.2.3.4 Key Personnels
    • 3.2.3.5 Analyst View
  • 3.2.4 Ionis Pharmaceuticals
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers / End Users
    • 3.2.4.4 Key Personnels
    • 3.2.4.5 Analyst View
  • 3.2.5 MediciNova
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers / End Users
    • 3.2.5.4 Key Personnels
    • 3.2.5.5 Analyst View
  • 3.2.6 AB Science
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers / End Users
    • 3.2.6.4 Key Personnels
    • 3.2.6.5 Analyst View
  • 3.2.7 Brainstorm-Cell Therapeutics
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers / End Users
    • 3.2.7.4 Key Personnels
    • 3.2.7.5 Analyst View
  • 3.2.8 Italfarmaco S.p.A.
    • 3.2.8.1 Company Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers / End Users
    • 3.2.8.4 Key Personnels
    • 3.2.8.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Amyotrophic Lateral Sclerosis Market, Coverage
• Figure: Global Amyotrophic Lateral Sclerosis Market, Key Trends, Impact Analysis
• Figure: Global Amyotrophic Lateral Sclerosis Market, Competitive Landscape, January 2022- April 2025

List of Tables

• Table: Global Amyotrophic Lateral Sclerosis Market, Dynamics and Impact Analysis
• Table: Global Amyotrophic Lateral Sclerosis Market, Regulatory Landscape
• Table: Global Amyotrophic Lateral Sclerosis Market, (by Region), $Million, 2023-2035